Abstract
Recent results from high-throughput and other screening approaches reveal that small molecules can directly interact with recombinant full-length tau monomers and fibrillar tau aggregates in three distinct modes. First, in the high concentration regime ( > 10 micromolar), certain anionic molecules such as Congo red efficiently promote tau filament formation through a nucleation-elongation mechanism involving a dimeric nucleus and monomer-mediated elongation. These compounds are useful for modeling tau aggregation in vitro and in biological models. Second, in the low concentration regime ( < 1 micromolar), other ligands, including cyanine dyes, display aggregation antagonist activity. Compounds that can prevent or reverse fibrillization are candidate modifiers of disease pathology. Finally, certain compounds bind mature tau fibrils with varying affinities at multiple binding sites without modulating the aggregation reaction. For some ligands, > 10-fold selectivity for tau aggregates relative to filaments composed of beta-amyloid or alpha-synuclein can be demonstrated at the level of binding affinity. Together these observations suggest that small-molecules have utility for interrogating the tau aggregation pathway, for inhibiting neuritic lesion formation, and for selective pre-mortem detection of neurofibrillary lesions through whole brain imaging.
Keywords: Alzheimer's disease, frontotemporal lobar degeneration, tau, neurofibrillary tangle, paired helical filaments, aggregation
Current Alzheimer Research
Title: Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Volume: 6 Issue: 5
Author(s): Edward Chang, Nicolette S. Honson, Bhaswati Bandyopadhyay, Kristen E. Funk, Jordan R. Jensen, Sohee Kim, Swati Naphade and Jeff Kuret
Affiliation:
Keywords: Alzheimer's disease, frontotemporal lobar degeneration, tau, neurofibrillary tangle, paired helical filaments, aggregation
Abstract: Recent results from high-throughput and other screening approaches reveal that small molecules can directly interact with recombinant full-length tau monomers and fibrillar tau aggregates in three distinct modes. First, in the high concentration regime ( > 10 micromolar), certain anionic molecules such as Congo red efficiently promote tau filament formation through a nucleation-elongation mechanism involving a dimeric nucleus and monomer-mediated elongation. These compounds are useful for modeling tau aggregation in vitro and in biological models. Second, in the low concentration regime ( < 1 micromolar), other ligands, including cyanine dyes, display aggregation antagonist activity. Compounds that can prevent or reverse fibrillization are candidate modifiers of disease pathology. Finally, certain compounds bind mature tau fibrils with varying affinities at multiple binding sites without modulating the aggregation reaction. For some ligands, > 10-fold selectivity for tau aggregates relative to filaments composed of beta-amyloid or alpha-synuclein can be demonstrated at the level of binding affinity. Together these observations suggest that small-molecules have utility for interrogating the tau aggregation pathway, for inhibiting neuritic lesion formation, and for selective pre-mortem detection of neurofibrillary lesions through whole brain imaging.
Export Options
About this article
Cite this article as:
Chang Edward, Honson S. Nicolette, Bandyopadhyay Bhaswati, Funk E. Kristen, Jensen R. Jordan, Kim Sohee, Naphade Swati and Kuret Jeff, Modulation and Detection of Tau Aggregation with Small-Molecule Ligands, Current Alzheimer Research 2009; 6 (5) . https://dx.doi.org/10.2174/156720509789207976
DOI https://dx.doi.org/10.2174/156720509789207976 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
miR-132 Down-regulates Methyl CpG Binding Protein 2 (MeCP2) During Cognitive Dysfunction Following Chronic Cerebral Hypoperfusion
Current Neurovascular Research Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia
CNS & Neurological Disorders - Drug Targets Inhalational Injury: A Brief Review of Pathophysiology, Diagnosis and Treatment
Current Respiratory Medicine Reviews Applicability and Approaches of (Meth) Acrylate Copolymers (Eudragits) in Novel Drug Delivery Systems
Current Drug Therapy Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets Hypersexuality As a Neuropsychiatric Disorder: The Neurobiology and Treatment Options
Current Drug Targets Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies
Current Alzheimer Research Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease
Current Alzheimer Research Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse
Current HIV Research Pro-inflammatory Cytokines Modulate Glial Apolipoprotein E Secretion
Current Alzheimer Research Multi-Nutrient Dietary Intervention Approach to the Management of Alzheimer’s Disease – A Mini-Review
Current Alzheimer Research Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued)